Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 antibodies ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly ...

There were 262,063.05 new cases, 2,742,285.75 prevalence, 115,973.98 deaths, and 2,260,975.34 DALYs of breast cancer among older adults in 2021 in Asia. From 1990 to 2021, the ASRs of breast cancer ...

As the complexity and need for cancer care services continue to grow, time to treatment initiation (TTI) has been increasing across cancer types. Presently there are no comprehensive analyses ...

Frustrations regarding the costs and difficulties with parking at hospitals is a common concern voiced by patients, families, and healthcare providers. Transportation barriers to receiving cancer care ...

Distress and isolation frequently affect individuals with cancer and oncology care providers. Both oncology care teams and patient communities play a crucial role in offering support during ...

Background: Amivantamab is a bispecific antibody that was granted accelerated approval by the FDA in May 2021 for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor ...

With that background, Birken et al 5 aimed to better understand the interplay between oncology and primary care in the follow-up of cancer survivors. The authors mined their electronic health record ...

LLMs demonstrated high accuracy in matching brand and generic names (GPT-4o: 97.38% for brand, 94.71% for generic, P < .01). However, they showed significant inconsistencies in word association tasks.

Background: The immune classification of tumor can be divided into immune infiltrating type, immune rejection type and immune desert type. There is little infiltration of CD8 + T cells in immune ...